HER2-Positive Colorectal Carcinoma — Trials

HER2-Positive Colorectal Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

6 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 3
Recruiting: 1
Ph III recruiting: 0
Growth YoY: —
Industry share: 67%
Top sponsor: Iambic Therapeutics, Inc
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04278144	A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors	terminated	Phase 1 / Phase 2	175	Bolt Biotherapeutics, Inc.INDUSTRY	4	Sep 15, 2025	clinicaltrials
NCT05985707	KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma	not yet recruiting	Phase 2	80	Peking University Cancer Hospital & InstituteOTHER	1	Aug 21, 2023